OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic Fibrosis

NCT04375878 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Exocrine Pancreatic Insufficiency (EPI)
Cystic Fibrosis (CF)

Interventions

DRUG: MS1819
DRUG: Porcine PERT

Sponsor

Entero Therapeutics